QIAGEN N.V is a diagnostics & research business based in the US. QIAGEN N-V shares (QGEN) are listed on the NYSE and all prices are listed in US Dollars. QIAGEN N-V employs 5,750 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in QIAGEN N-V
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – QGEN – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
What's in this guide?
- QGEN shares summary
- Compare share dealing platforms
- Is QGEN stock a buy or sell?
- Stock performance over time
- Can I short QGEN shares?
- Is QGEN suitable for ethical investing?
- Are QGEN shares over-valued?
- QIAGEN N-V's financials
- How volatile are QGEN shares?
- Does QIAGEN N-V pay a dividend?
- Have QGEN shares ever split?
- Other common questions
QIAGEN N-V stock price (NYSE: QGEN)Use our graph to track the performance of QGEN stocks over time.
QIAGEN N-V shares at a glance
|Latest market close||$49.36|
|52-week range||$45.33 - $59.00|
|50-day moving average||$48.92|
|200-day moving average||$50.08|
|Wall St. target price||$58.56|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$1.92|
Buy QIAGEN N-V shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy QIAGEN N-V stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
QIAGEN N-V price performance over time
|1 week (2021-07-22)||N/A|
|1 month (2021-07-02)||-0.28%|
|3 months (2021-04-30)||2.56%|
|6 months (2021-01-29)||N/A|
|1 year (2020-07-29)||N/A|
|2 years (2019-07-29)||N/A|
|3 years (2018-07-29)||N/A|
|5 years (2016-07-29)||N/A|
Is QIAGEN N-V under- or over-valued?
Valuing QIAGEN N-V stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of QIAGEN N-V's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
QIAGEN N-V's P/E ratio
QIAGEN N-V's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 27x. In other words, QIAGEN N-V shares trade at around 27x recent earnings.
That's comparable to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29).
QIAGEN N-V's PEG ratio
QIAGEN N-V's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 4.42. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into QIAGEN N-V's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
QIAGEN N-V's EBITDA
QIAGEN N-V's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $794.6 million.
The EBITDA is a measure of a QIAGEN N-V's overall financial performance and is widely used to measure a its profitability.
QIAGEN N-V financials
|Revenue TTM||$2.1 billion|
|Operating margin TTM||28.56%|
|Gross profit TTM||$1.3 billion|
|Return on assets TTM||6.74%|
|Return on equity TTM||16.8%|
|Market capitalisation||$11.9 billion|
TTM: trailing 12 months
Shorting QIAGEN N-V shares
There are currently 5.1 million QIAGEN N-V shares held short by investors – that's known as QIAGEN N-V's "short interest". This figure is 17.9% up from 4.3 million last month.
There are a few different ways that this level of interest in shorting QIAGEN N-V shares can be evaluated.
QIAGEN N-V's "short interest ratio" (SIR)
QIAGEN N-V's "short interest ratio" (SIR) is the quantity of QIAGEN N-V shares currently shorted divided by the average quantity of QIAGEN N-V shares traded daily (recently around 834971.16968699). QIAGEN N-V's SIR currently stands at 6.07. In other words for every 100,000 QIAGEN N-V shares traded daily on the market, roughly 6070 shares are currently held short.
However QIAGEN N-V's short interest can also be evaluated against the total number of QIAGEN N-V shares, or, against the total number of tradable QIAGEN N-V shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case QIAGEN N-V's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 QIAGEN N-V shares in existence, roughly 20 shares are currently held short) or 0.0224% of the tradable shares (for every 100,000 tradable QIAGEN N-V shares, roughly 22 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against QIAGEN N-V.
Find out more about how you can short QIAGEN N-V stock.
QIAGEN N-V's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like QIAGEN N-V.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
QIAGEN N-V's total ESG risk score
Total ESG risk: 16.36
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and QIAGEN N-V's overall score of 16.36 (as at 12/31/2018) is excellent – landing it in it in the 14th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like QIAGEN N-V is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
QIAGEN N-V's environmental score
Environmental score: 1.25/100
QIAGEN N-V's environmental score of 1.25 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that QIAGEN N-V is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
QIAGEN N-V's social score
Social score: 8.53/100
QIAGEN N-V's social score of 8.53 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that QIAGEN N-V is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
QIAGEN N-V's governance score
Governance score: 6.07/100
QIAGEN N-V's governance score puts it squarely in the 2nd percentile of companies rated in the same sector. That could suggest that QIAGEN N-V is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
QIAGEN N-V's controversy score
Controversy score: 1/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. QIAGEN N-V scored a 1 out of 5 for controversy – the highest score possible, reflecting that QIAGEN N-V has managed to keep its nose clean.
Environmental, social, and governance (ESG) summary
|Total ESG score||16.36|
|Total ESG percentile||13.68|
|Environmental score percentile||2|
|Social score percentile||2|
|Governance score percentile||2|
|Level of controversy||1|
QIAGEN N-V share dividends
We're not expecting QIAGEN N-V to pay a dividend over the next 12 months.
Have QIAGEN N-V's shares ever split?
QIAGEN N-V's shares were split on a 962:1000 basis on 24 January 2017. So if you had owned 1000 shares the day before before the split, the next day you'd have owned 962 shares. This wouldn't directly have changed the overall worth of your QIAGEN N-V shares – just the quantity. However, indirectly, the new 4% higher share price could have impacted the market appetite for QIAGEN N-V shares which in turn could have impacted QIAGEN N-V's share price.
QIAGEN N-V share price volatility
Over the last 12 months, QIAGEN N-V's shares have ranged in value from as little as $45.33 up to $59. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while QIAGEN N-V's is 0.2394. This would suggest that QIAGEN N-V's shares are less volatile than average (for this exchange).
QIAGEN N-V overview
QIAGEN N. V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for analysis of genomic variants; and assays for prenatal testing and detection of sexually transmitted diseases and HPV; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers PCR consumables, such as quantitative PCR, reverse transcription and combinations kits for analysis of gene expression, genotyping and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. It offers predefined and custom NGS gene panels, library prep kits and components, whole genome amplification, etc.
QIAGEN N-V in the news
3 Must-Own Healthcare Stocks For Your Portfolio
QIAGEN (QGEN) Q2 Earnings Top Estimates, Margins Decline
Qiagen Stock Gains As Non COVID Sales Boosts Q2 Topline, Bottom-line
Frequently asked questionsWhat percentage of QIAGEN N-V is owned by insiders or institutions?
Currently 0.704% of QIAGEN N-V shares are held by insiders and 72.55% by institutions. How many people work for QIAGEN N-V?
Latest data suggests 5,750 work at QIAGEN N-V. When does the fiscal year end for QIAGEN N-V?
QIAGEN N-V's fiscal year ends in December. Where is QIAGEN N-V based?
QIAGEN N-V's address is: Hulsterweg 82, Venlo, Netherlands, 5912 PL What is QIAGEN N-V's ISIN number?
QIAGEN N-V's international securities identification number is: NL0012169213 What is QIAGEN N-V's CUSIP number?
QIAGEN N-V's Committee on Uniform Securities Identification Procedures number is: N72482107
More guides on Finder
How to buy Argus Capital Corp (ARGU) stock when it goes public
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
How to buy RenovoRx (RNXT) stock when it goes public
Everything we know about the RenovoRx IPO, plus information on how to buy in.
How to buy Draganfly (DPRO) stock when it goes public
Everything we know about the Draganfly IPO, plus information on how to buy in.
How to buy Society Pass Incorporated (SOPA) stock when it goes public
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
How to buy Guardforce AI Co (GFAI) stock when it goes public
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
How to buy IsoPlexis Corporation (ISO) stock when it goes public
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
How to buy Marpai (MRAI) stock when it goes public
Everything we know about the Marpai IPO, plus information on how to buy in.
How to buy DoubleDown Interactive (DDI) stock when it goes public
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
How to buy Omniq Corp (OMQS) stock when it goes public
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
How to buy Mechanical Technology (MKTYP) stock when it goes public
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
Ask an Expert